MX2011000437A - Variantes de hemaglutinina y neuramnidasa de influenza. - Google Patents

Variantes de hemaglutinina y neuramnidasa de influenza.

Info

Publication number
MX2011000437A
MX2011000437A MX2011000437A MX2011000437A MX2011000437A MX 2011000437 A MX2011000437 A MX 2011000437A MX 2011000437 A MX2011000437 A MX 2011000437A MX 2011000437 A MX2011000437 A MX 2011000437A MX 2011000437 A MX2011000437 A MX 2011000437A
Authority
MX
Mexico
Prior art keywords
influenza hemagglutinin
neuraminidase variants
neuraminidase
variants
hemagglutinin
Prior art date
Application number
MX2011000437A
Other languages
English (en)
Inventor
George Kemble
Chin-Fen Yang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2011000437A publication Critical patent/MX2011000437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan polipéptidos, polinucleótidos, métodos, composiciones, y vacunas que comprenden variantes de hemaglutinina y neuraminidasa de influenza.
MX2011000437A 2008-07-11 2009-07-09 Variantes de hemaglutinina y neuramnidasa de influenza. MX2011000437A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7989408P 2008-07-11 2008-07-11
US11070208P 2008-11-03 2008-11-03
US17859209P 2009-05-15 2009-05-15
PCT/US2009/050070 WO2010006144A2 (en) 2008-07-11 2009-07-09 Influenza hemagglutinin and neuraminidase variants

Publications (1)

Publication Number Publication Date
MX2011000437A true MX2011000437A (es) 2012-03-07

Family

ID=41507727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011000437A MX2011000437A (es) 2008-07-11 2009-07-09 Variantes de hemaglutinina y neuramnidasa de influenza.

Country Status (11)

Country Link
US (1) US8591914B2 (es)
EP (2) EP2318043A4 (es)
JP (2) JP2011527581A (es)
CN (1) CN102149405A (es)
AU (1) AU2009268576B2 (es)
BR (1) BRPI0915487A2 (es)
CA (1) CA2730408A1 (es)
MX (1) MX2011000437A (es)
RU (1) RU2523587C2 (es)
SG (1) SG192501A1 (es)
WO (1) WO2010006144A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2318043A4 (en) 2008-07-11 2012-01-25 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN104114186B (zh) * 2011-08-03 2017-05-03 儿童医疗中心有限公司 识别流行性感冒血凝素的受体‑结合袋状结构的广泛中和人类抗体
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
MX2015008847A (es) * 2013-01-10 2015-10-30 Novartis Ag Composiciones inmunogenicas de virus de influenza y usos de las mismas.
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2015061475A2 (en) 2013-10-22 2015-04-30 THE GOVERNMENT OF THE USA as represented by THE SECRETARY OF THE DEPARTMENT OF HEATLH AND HUMAN SERV Compositions and methods for detection and discrimination of influenza viruses
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
CN108048476B (zh) 2017-11-21 2020-09-08 浙江迪福润丝生物科技有限公司 一种制备区分免疫和感染动物h9亚型禽流感疫苗株的方法及应用
CN108018300B (zh) * 2017-11-21 2020-08-28 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) * 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
ES2247584T3 (es) 1992-04-14 2006-03-01 The Mount Sinai School Of Medicine Of The City University Of New York Virus atenuados por ingenieria genetica.
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
RU2100033C1 (ru) * 1995-10-05 1997-12-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения вакцинных штаммов вируса гриппа в для производства инактивированных и живых гриппозных вакцин
CN1118569C (zh) 1995-10-31 2003-08-20 株式会社载体研究所 具有自主复制能力的负链rna病毒载体
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
US6090391A (en) * 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
CA2265554A1 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
CA2295858C (en) 1997-07-11 2011-05-10 Yale University Rhabdoviruses with reengineered coats
JP2001517448A (ja) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
PT1820853E (pt) 1999-04-06 2012-01-03 Wisconsin Alumni Res Found Vírus recombinante da gripe para vacinas e terapia genética
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
RU2280690C2 (ru) * 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Рекомбинантные вирусы гриппа а
KR100848719B1 (ko) 2000-04-28 2008-07-25 세인트 쥬드 칠드런즈 리써치 호스피탈 감염성 인플루엔자 바이러스 생성용 ｄｎａ 트랜스펙션시스템
WO2002024876A2 (en) * 2000-09-25 2002-03-28 Polymun Scientific Immunbiologische Forschung Gmbh Live influenza vaccine and method of manufacture
DE60239594D1 (de) * 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
KR101229202B1 (ko) * 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN100482788C (zh) * 2003-04-10 2009-04-29 中国疾病预防控制中心病毒病预防控制所 高产的重组乙型流感病毒株及其用途
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CN1644686B (zh) * 2003-10-08 2010-05-12 中国疾病预防控制中心病毒病预防控制所 流感病毒哺乳动物细胞高产毒株、其重组毒株及其制备方法和应用
EP1771552B1 (en) * 2004-05-25 2012-08-01 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2006049061A1 (ja) 2004-11-01 2006-05-11 Eiken Kagaku Kabushiki Kaisha Ｈ５型又はｈ７型トリインフルエンザウイルスの検出方法
CA2586690A1 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
AU2005322353B2 (en) * 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
EP2441471B1 (en) * 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
ES2534332T3 (es) * 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
CA2676028A1 (en) * 2007-01-18 2008-11-27 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2318043A4 (en) 2008-07-11 2012-01-25 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS

Also Published As

Publication number Publication date
CA2730408A1 (en) 2010-01-14
AU2009268576B2 (en) 2014-03-27
EP2318043A2 (en) 2011-05-11
SG192501A1 (en) 2013-08-30
BRPI0915487A2 (pt) 2017-06-27
EP2318043A4 (en) 2012-01-25
EP2574344A1 (en) 2013-04-03
US8591914B2 (en) 2013-11-26
JP2014158487A (ja) 2014-09-04
RU2523587C2 (ru) 2014-07-20
WO2010006144A2 (en) 2010-01-14
WO2010006144A3 (en) 2010-03-18
JP2011527581A (ja) 2011-11-04
AU2009268576A1 (en) 2010-01-14
RU2011104999A (ru) 2012-08-20
US20110212117A1 (en) 2011-09-01
CN102149405A (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
MX2011000437A (es) Variantes de hemaglutinina y neuramnidasa de influenza.
MX2012000123A (es) Variantes de hemaglutinina de la influenza porcina.
WO2008021959A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2006098901A3 (en) Influenza hemagglutinin and neuraminidase variants
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
IL231547B (en) Polypeptide of the chimeric hemagglutinin (ha) from an influenza virus, an immune composition containing it and its uses
HK1143085A1 (en) Low-additive influenza vaccines
WO2005116260A3 (en) Influenza hemagglutinin and neuraminidase variants
GB0810305D0 (en) Influenza vaccination
PL2043682T3 (pl) Szczepionka przeciw grypie
PT2043682E (pt) Vacina da influenza
IL213189A0 (en) Recombinant avian influenza vaccine and uses thereof
SG10201709806VA (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA200809056B (en) Influenza virus vaccine
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
ZA201100962B (en) Influenza vaccines
EP2640405A4 (en) TREATMENT AND / OR CHARACTERIZATION OF INFLUENZA; POLYPEPTIDES HA ADAPTED TO MAN
MX343411B (es) Variantes de hemaglutinina y neuraminidasa de influenza.
LT2482845T (lt) Nauja vakcinos kompozicija prieš gripą
EP2097103A4 (en) VACCINE FORMULATIONS AGAINST INFLUENZA
EP2368899B8 (en) Avian influenza vaccine
EP2310030A4 (en) NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUSES
EP2240199A4 (en) INFLUENZA VACCINES
ZA200900062B (en) Influenza vaccine

Legal Events

Date Code Title Description
FG Grant or registration